Daily News
From Home Furnishing Business
PureCare Mattress Protector Certified to Block Viruses including COVID-19
June 10,
2020 by Laurie Northington in Business Strategy, Industry 
PureCare, a resource for mattress and pillow protectors, sheets, and pillows, has announced the recent certification of its proprietary OmniGuard Advance mattress cover as effective in blocking viruses such as COVID-19.
The PureCare OmniGuard Advance five-sided and total encasement mattress covers attained the Vartest certification that meets ASTM F1671 viral penetration testing standard for resistance to bloodborne pathogens.
The ASTM F1671 test method established by the U.S. Centers for Disease Control and Prevention determines whether a fabric can block Phi-X174 bacteriophage, a virus that is about 32 nanometers in diameter. COVID-19 is approximately 125 nanometers in diameter.
“PureCare has a long history of working with a variety of wellness experts and laboratories who clinically test our products in order to ensure the transparency and accuracy of all of our claims,” said Sean Bergman, chief operating officer. “Our recent Vartest certification adds another layer of scientific validation for our retailers and customers who are looking for cleaner, more hygienic sleep products.”
PureCare’s OmniGuard Advance fabric serves as the base fabric throughout their collection of premium, clinically proven mattress and pillow protectors. The fabric has a unique microdot design that allows it to be washed and dried hot for complete sanitization and is treated with antimicrobial silver chloride product protection that inhibits bacteria, mold and mildew that cause odors, stains and deterioration on the products. These and other features have helped to earn PureCare’s protector collection the official seals of the National Sleep Foundation and the Women’s Choice Award.
The certification of OmniGuard Advance fabric bolsters PureCare’s mission and portfolio of products designed to enhance the sleep environment, including its Celliant sleep products designed to temporarily increase blood flow at the site of application in healthy individuals and improve physical recovery time and sleep quality. In 2017, the U.S. Food and Drug Administration determined Celliant products are medical devices and general wellness products (as defined in section 201(h) of the Federal Food, Drug and Cosmetic Act).